Evidence map›Paper›PMID 36059919›Full record

ArticleIJID regions2022

Demographic, clinical, and outcome characteristics of carbapenem-resistant Enterobacteriaceae over a 10-year period (2010-2020) in Oman.

Faryal Khamis, Ibrahim Al-Zakwani, Mariya Molai, Jalila Mohsin, Samta Al Dowaiki, Maher Al Bahrani, Eskild Petersen

Abstract read
In one paragraph

Article in IJID regions, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Faryal KhamisInfectious Diseases Unit, Department of Internal Medicine, Royal Hospital, Muscat, Oman.
Ibrahim Al-ZakwaniDepartment of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
Mariya MolaiInfectious Diseases Unit, Department of Internal Medicine, Royal Hospital, Muscat, Oman.
Jalila MohsinDepartment of Microbiology, Royal Hospital, Muscat, Oman.
Samta Al DowaikiInfectious Diseases Unit, Department of Internal Medicine, Royal Hospital, Muscat, Oman.
Maher Al BahraniDepartment of Anesthesia and Critical Care, Royal Hospital, Muscat, Oman.
Eskild PetersenInfectious Diseases Unit, Department of Internal Medicine, Royal Hospital, Muscat, Oman.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The incidence of carbapenem-resistant Enterobacteriaceae (CRE) has increased in the last two decades, causing significant morbidity and mortality. Our study investigated the factors associated with mortality from CRE bloodstream infection in a single center in Oman. Methods: Data from adult patients with CRE bacteremia, over a 10-year period, were retrospectively collected. Demographic and clinical characteristics were compared according to intensive care unit (ICU) admission status and mortality. A logistic regression model was used to evaluate factors associated with mortality. Results: 169 cases of CRE bacteremia were identified, of whom 93 (55%) required ICU admission and 96 (56.8%) died. Patients who required ICU care were more likely to require organ transplant (15% vs 4.0%; Conclusion: CRE bacteremia carries a high mortality rate in patients requiring ICU care. Implementation of infection control measures and antimicrobial stewardship programs are essential in reducing the rates of CRE BSI.

Indexed as

bacteremiabloodstream infectioncarbapenemasecarbapenemase-producingcarbapenem resistancecarbapenem-resistant EnterobacteriaceaedeathsEnterobacteriaceaeKlebsiella pneumoniaeKlebsiella pneumoniae carbapenemasemortalityoutcomeprognostic factor

Identifiers

PMID36059919
PMCPMC9428798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.